Advertisement


Tony Mok, MD, on NSCLC: Results From the ARCHER 1050 Trial

2018 ASCO Annual Meeting

Advertisement

Tony Mok, MD, of the Chinese University of Hong Kong, discusses study findings on dacomitinib vs gefitinib for first-line treatment of advanced non–small cell lung cancer, a final overall survival analysis.



Related Videos

Kidney Cancer
Immunotherapy

Bernard J. Escudier, MD, on RCC: Results From the IMmotion151 Trial

Bernard J. Escudier, MD, of Gustave Roussy, discusses patient-reported outcomes for atezolizumab plus bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma (A...

Hematologic Malignancies
Immunotherapy

Meletios A. Dimopoulos, MD, on Waldenström’s Macroglobulinemia

Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, discusses phase III findings on ibrutinib/rituximab vs placebo/rituximab in Waldenström’s macrogl...

Prostate Cancer

Daniel J. George, MD, on Prostate Cancer: Outcomes for Black and White Patients

Daniel J. George, MD, of Duke University, discusses findings from a multicenter study of black and white patients with metastatic castrate-resistant prostate cancer treated with ab...

Gynecologic Cancers
Immunotherapy

David M. O’Malley, MD, on Ovarian Cancer: Early Results From the FORWARD II Study

David M. O’Malley, MD, of The Ohio State University College of Medicine, discusses phase Ib study findings on mirvetuximab soravtansine, a folate receptor alpha-targeting antibody-...

Breast Cancer

Andrew D. Seidman, MD, and Aditya Bardia, MD, MPH, on Metastatic Breast Cancer: Findings on an Antibody-Drug Conjugate

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discuss the efficacy of sacituzuma...

Advertisement

Advertisement



Advertisement